– USA, CA – Contineum Therapeutics, Inc. (Nasdaq: CTNM), a clinical-stage biopharmaceutical company, today announced the appointment of Sarah Boyce to its Board as an independent Director, bringing over 25 years of global commercial and clinical development expertise in the life sciences industry to the board.
“I am delighted to continue these efforts with the addition of Sarah Boyce to Contineum’s Board of Directors. Sarah’s appointment brings a tremendous wealth of knowledge in translating innovation into products, including in rare diseases, and we look forward to her guidance as we seek to advance our NI&I pipeline toward patients,” said CEO Carmine Stengone.
About Sarah Boyce
Sarah Boyce has extensive expertise in global pharmaceutical product development and commercialization, business operations, strategic planning, and execution, and has a proven track record of successfully bringing over 20 products to market and scaling companies. Currently, she serves as President and CEO and as a member of the Board of Directors of Avidity Biosciences, Inc. (Nasdaq: RNA). Before joining Avidity, Sarah Boyce served as a Director and President of Akcea Therapeutics, Inc. (Nasdaq: AKCA), and as CBO at Ionis Pharmaceuticals, Inc. (Nasdaq: IONS), where she was responsible for business development, alliance management, patient advocacy, and investor relations. Before Ionis, she served as VP and head of International Business Strategy and Operations at Forest Laboratories, Inc., and held various positions of increasing responsibility with Alexion Pharmaceuticals Inc., Novartis Group AG (NYSE: NVS), Bayer AG, and F. Hoffmann-La Roche AG. Ms. Boyce also previously served on the Board of Directors of Berkeley Lights Inc. (Nasdaq: BLI) and currently serves on the board of directors of OmniAb, Inc.
“Contineum has a clear focus on seeking to address the significant unmet needs of patients with serious fibrotic and neurological disorders. I am excited about Contineum’s science and development programs and I believe Contineum has a very bright future,” said Sarah Boyce. “I am excited to join the board and to help Contineum navigate its next stages of growth.”
Sarah Boyce received a B.S. degree in microbiology from the University of Manchester, England.
About Contineum Therapeutics
Contineum Therapeutics is a clinical-stage biopharmaceutical company focused on discovering and developing novel, oral small-molecule therapies for NI&I indications with high unmet needs. Contineum is focused on targeting biological pathways associated with specific clinical impairments, that Contineum believes, once modulated, may demonstrably impact the course of the disease. Contineum has a pipeline of internally developed programs to address multiple NI&I disorders. PIPE-791 is an LPA1 receptor antagonist that recently completed a Phase 1 healthy volunteer clinical trial to support ongoing clinical development for idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). PIPE-307, a selective inhibitor of the M1 receptor, is currently in a Phase 2 clinical trial for relapse remitting MS, and a Phase 2 trial in depression is planned to be initiated in 2024. Contineum is developing PIPE-307 in collaboration with Johnson & Johnson Innovative Medicines.
For more: https://www.contineum-tx.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.